Nothing Special   »   [go: up one dir, main page]

ATE536880T1 - Impfstoff beinhaltend amb a 1 peptide zur behandlung von traubenkraut-allergie - Google Patents

Impfstoff beinhaltend amb a 1 peptide zur behandlung von traubenkraut-allergie

Info

Publication number
ATE536880T1
ATE536880T1 AT09251252T AT09251252T ATE536880T1 AT E536880 T1 ATE536880 T1 AT E536880T1 AT 09251252 T AT09251252 T AT 09251252T AT 09251252 T AT09251252 T AT 09251252T AT E536880 T1 ATE536880 T1 AT E536880T1
Authority
AT
Austria
Prior art keywords
allergy
rape
peptides
treatment
ragweed
Prior art date
Application number
AT09251252T
Other languages
English (en)
Inventor
Mark Larche
Roderick Peter Hafner
Paul Laidler
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41090318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE536880(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0814986A external-priority patent/GB0814986D0/en
Priority claimed from GB0815218A external-priority patent/GB0815218D0/en
Application filed by Circassia Ltd filed Critical Circassia Ltd
Application granted granted Critical
Publication of ATE536880T1 publication Critical patent/ATE536880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT09251252T 2008-08-15 2009-05-01 Impfstoff beinhaltend amb a 1 peptide zur behandlung von traubenkraut-allergie ATE536880T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0814986A GB0814986D0 (en) 2008-08-15 2008-08-15 Peptide for il10 production
GB0815218A GB0815218D0 (en) 2008-08-20 2008-08-20 Ragweed peptides for vaccine

Publications (1)

Publication Number Publication Date
ATE536880T1 true ATE536880T1 (de) 2011-12-15

Family

ID=41090318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09251252T ATE536880T1 (de) 2008-08-15 2009-05-01 Impfstoff beinhaltend amb a 1 peptide zur behandlung von traubenkraut-allergie

Country Status (18)

Country Link
US (3) US8491910B2 (de)
EP (3) EP2153841B2 (de)
JP (1) JP5788319B2 (de)
KR (1) KR20110044787A (de)
CN (2) CN104710512A (de)
AT (1) ATE536880T1 (de)
AU (1) AU2009281013B2 (de)
BR (1) BRPI0917648A2 (de)
CA (1) CA2734379A1 (de)
DK (1) DK2153841T4 (de)
EA (1) EA201170336A1 (de)
ES (1) ES2378870T5 (de)
HR (1) HRP20120206T4 (de)
MX (1) MX2011001619A (de)
PL (1) PL2153841T5 (de)
PT (1) PT2153841E (de)
SI (1) SI2153841T2 (de)
WO (1) WO2010018378A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958645A1 (de) * 2007-02-13 2008-08-20 Biomay AG Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
PT2153841E (pt) * 2008-08-15 2012-03-21 Circassia Ltd Vacina compreendendo péptidos amb a 1 para utilização no tratamento de alergia a ambrósia
WO2010018384A1 (en) * 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
EP3170510A1 (de) * 2010-01-14 2017-05-24 Merck Patent GmbH Varianten der gruppe 5-allergene der süssgräser mit reduzierter allergenität durch mutagenese von prolinresten
FI20115374A0 (fi) * 2011-04-18 2011-04-18 Teknologian Tutkimuskeskus Vtt Oy Uudet hypoallergeenit
CA2839832C (en) * 2011-06-27 2018-08-28 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
AU2013248275B2 (en) * 2012-04-16 2017-03-30 Alk-Abello A/S Plant profilin polypeptides for use in non-specific allergy immunotherapy
MX2015005636A (es) 2012-10-30 2015-11-16 Univ Monash Moléculas inmunoterapéuticas novedosas y sus usos.
US11173206B2 (en) 2013-03-15 2021-11-16 Sementis Limited Immune modulation
CA2925480A1 (en) 2013-09-25 2015-04-02 Aravax Pty Ltd Novel immunotherapeutic composition and uses thereof
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
EP3295956A1 (de) * 2016-09-20 2018-03-21 Biomay Ag Polypeptidkonstrukt mit fragmenten von allergenen
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776761A (en) * 1989-03-17 1998-07-07 Immulogic Pharmaceutical Corporation Nucleic acids encoding allergenic proteins from ragweed
EP0463059B1 (de) 1989-03-17 1998-12-30 Immulogic Pharmaceutical Corporation Allergene proteine aus ambrosia und verwendung davon
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
EP0770681A3 (de) 1992-04-09 1997-06-04 Immulogic Pharmaceutical Corporation T-Zellen Epitopen der Hauptallergenen von Ambrosia artemisiifolia
JPH07257419A (ja) 1994-03-24 1995-10-09 Kubota Corp 農作業車
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
AU4146796A (en) * 1994-10-27 1996-05-23 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
AU2064899A (en) 1998-01-09 1999-07-26 Circassia Limited Methods and compositions for desensitisation
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
GB0210741D0 (en) 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
WO2006075253A2 (en) 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
US7718622B2 (en) * 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
EP1899367A4 (de) 2005-06-10 2009-06-24 Univ Singapore Mutantes allergen/mutante allergene
US20070092532A1 (en) 2005-10-25 2007-04-26 Board Of Trustees Operating Michigan State University Arthritis vaccines and methods
CN100457180C (zh) * 2005-11-09 2009-02-04 浙江我武生物科技有限公司 用于治疗过敏性疾病的药物组合物及其制备方法
EP1957100B1 (de) 2005-11-29 2016-07-13 Intrexon Actobiotics NV Induktion von schleimhauttoleranz gegen antigene
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP1958645A1 (de) * 2007-02-13 2008-08-20 Biomay AG Peptide abgeleitet vom Hauptallergens von Traubenkraut (Ambrosia artemisiifolia) und deren Anwendung
ES2425486T3 (es) 2007-05-09 2013-10-15 Circassia Limited Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
PT2153841E (pt) * 2008-08-15 2012-03-21 Circassia Ltd Vacina compreendendo péptidos amb a 1 para utilização no tratamento de alergia a ambrósia

Also Published As

Publication number Publication date
CN102170897A (zh) 2011-08-31
MX2011001619A (es) 2011-03-25
WO2010018378A3 (en) 2010-07-22
SI2153841T1 (sl) 2012-04-30
JP5788319B2 (ja) 2015-09-30
EP2433639A3 (de) 2012-06-27
DK2153841T4 (en) 2016-02-15
KR20110044787A (ko) 2011-04-29
EP2433639A2 (de) 2012-03-28
US20130295123A1 (en) 2013-11-07
HRP20120206T4 (hr) 2016-02-12
WO2010018378A2 (en) 2010-02-18
ES2378870T5 (es) 2016-02-03
US20170014505A1 (en) 2017-01-19
BRPI0917648A2 (pt) 2015-12-01
HRP20120206T1 (en) 2012-03-31
US20120108524A1 (en) 2012-05-03
AU2009281013A1 (en) 2010-02-18
JP2012500193A (ja) 2012-01-05
CA2734379A1 (en) 2010-02-18
AU2009281013B2 (en) 2015-01-29
EP2444100A3 (de) 2012-07-25
EP2153841B2 (de) 2015-11-11
EA201170336A1 (ru) 2011-10-31
WO2010018378A8 (en) 2010-10-28
US8491910B2 (en) 2013-07-23
EP2444100A2 (de) 2012-04-25
DK2153841T3 (da) 2012-03-26
EP2153841A1 (de) 2010-02-17
SI2153841T2 (sl) 2016-02-29
PL2153841T3 (pl) 2012-05-31
PT2153841E (pt) 2012-03-21
PL2153841T5 (pl) 2016-09-30
CN104710512A (zh) 2015-06-17
US9347937B2 (en) 2016-05-24
ES2378870T3 (es) 2012-04-18
EP2153841B1 (de) 2011-12-14
CN102170897B (zh) 2015-02-04

Similar Documents

Publication Publication Date Title
ATE536880T1 (de) Impfstoff beinhaltend amb a 1 peptide zur behandlung von traubenkraut-allergie
CY1123304T1 (el) Αναστολη πεπτιδιων που προερχονται απο μεταγραφημα 1 τυπου trem (tlt-1) και χρησεις αυτωn
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
EA201200515A1 (ru) Полипептиды и их применение
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
DE602006016133D1 (de) Verwendung von stefin a als gerüstprotein
DE602007014210D1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
ATE473756T1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
MX2020012569A (es) Moleculas inmunoterapeuticas novedosas y sus usos.
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
ES2550705T3 (es) Proteínas quiméricas hipoalergénicas pertenecientes a la familia de transferencia de lípidos de Parietaria judaica para usar en el tratamiento de alergias
ATE400581T1 (de) Peptid-antioxidantien aus sojaproteinen
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof
WO2012073045A3 (en) Variants of trappins
WO2008070586A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2016209959A2 (en) Peptide combinations and use thereof in treating cedar pollen allergy
ATE524492T1 (de) Hypoallergene proteine abgeleitet vom hauptallergen von parietaria judaica
Pyoung et al. Characterization of the 36kDa Sperminogen by MALDI-MS and Peptide Sequence Analyses in boar Spermatozoa